Understanding the Mechanism of Action of Rotigotine API in Parkinson's Disease Treatment
Rotigotine API produced by major manufacturers like Uquifa and Neuland Laboratories plays a key role in Parkinson's disease drugs through its specific neuropharmacological profile.
Loss of dopamine-producing neurons in the substantia nigra pars compacta leads to striatal dopamine deficiency, manifesting as motor impairment.
Rotigotine acts as a non-selective dopamine receptor agonist, mimicking dopamine's actions by binding to D1-D5 subtypes in nigrostriatal and mesocortical pathways.
This stimulates G-protein coupled, second messenger cascades that increase neuronal excitability and elevate motor function-regulating neurotransmitters like glutamate.
The net result is enhanced dopaminergic neurotransmission, compensating for the underlying loss of endogenous dopamine. Common Parkinson's motor symptoms improve as shown below:
Symptom Mechanism Tremor Increased striatal glutamate outflow Rigidity Enhanced globus pallidus inhibition Bradykinesia Facilitated motor circuit excitationTherefore, high-quality rotigotine API forms the pharmacological basis for an important non-levodopa treatment approach in Parkinson's disease.
Copyright ©2025